FDA approves Medtronic’s “artificial pancreas”

FDA has approved Medtronic’s MiniMed 670G hybrid closed looped system. This is the first device approved by the US Agency that monitors glucose and allows to deliver the appropriate dose of basal insulin in patients with type-1 diabetes, 14 years of age and older. The pancreas physiologically provides a continuous amount of insulin, referred to as basal secretion. Production of such secretion is altered or impaired in diabetes patients. The Medtronic device, often referred to as an “artificial pancreas”, is designed to adjust insulin levels almost automatically. It works by measuring glucose levels every five minutes and automatically administering or withholding insulin. The system includes a sensor that attaches to the body to measure glucose levels under the skin; an insulin pump strapped to the body; and an insulin infusion patch connected to the pump through a catheter. The approval follows the results of a clinical trial that included 123 participants with type 1 diabetes.
(Source FDA)